Forschungsverbund Berlin E.v.

Max-Delbrueck-Centrum Fuer Molekulare Medizin

Pharmos Bioscience A/s

Max-Delbruck-Centrum Fur Molekulare Medizin in Der Helmholtz-Gemeinschaft

Thomas Jentsch

Jens Fuhrmann

Tobias Stauber

Philipp Lange

Felizia K Voss

The invention relates to a method for the identification of a channel modulator, such as an agonist or antagonist, that interacts with one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E and/or protein complexes thereof. The invention further relates to an isolated heteromeric protein complex comprising one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E for use in such methods, in addition to kits suitable for carrying out such methods. The invention therefore relate preferably to the use of LRRC8 proteins and complexes thereof for the identification of VRAC (VSOAC) modulators.

LRRC8 proteins and protein complexes and methods for identification of channel modulators

A method for screening a test compound for activity in modulating the activity of the chloride channel ClC-7 either directly or by modulating the subcellular localization of Ostm1 comprises determining whether test compound inhibits the binding of Ostm1 to ClC-7. Compounds active in the screen are candidates for use in treating bone resorption conditions such as Osteoporosis by modulating the activity of osteoclasts.

Screening compounds for activity in modulating chloride ion transport

Growing community of inventors

Berlin, Germany

Thomas Jentsch